Shots:

• The REFLECTIONS B328-06 study involves assessing of PF-05280586 vs Rituxan/MabThera (rituximab) in patients with 1L CD20-positive- low tumor burden- follicular lymphoma evaluating its efficacy- safety and immunogenicity- PK and PD
• The study demonstrated meeting of 1EPs as OS @26 wks. (75.5% vs 70.7%) and PFS@ 1yrs (76.4% vs 81.2%) with similar safety & efficacy to MabThera
• PF-05280586 (rituximab biosimilar) is an mAb- indicated for CD20-positive chronic lymphocytic leukemia- RA- granulomatosis with polyangiitis and microscopic polyangiitis and other region-specific indications of and is currently reviewed by the US FDA with expected BsUFA date in H2’19

Ref: Pfizer | Image: Market Exclusive